Math Biology srl
Develops AI-native DMA® non-invasive screening of bioelectrical signals for metabolic digital twins in health.
Website: https://mathbiology.tech
Cover Block
| Attribute | Value |
|---|---|
| Name | Math Biology srl |
| Tagline | Develops AI-native DMA® non-invasive screening of bioelectrical signals for metabolic digital twins in health. [Perplexity Sonar Pro Brief] |
| Founded | 2020 |
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Geography | Western Europe (Italy) |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Total Disclosed Funding | $1.5M (estimated) [SignalBase] |
Links
- Website: https://mathbiology.tech/
- Website (alternate): https://mathbiology.ai/
- LinkedIn: https://www.linkedin.com/company/math-biology-srl/
- BIO International Convention 2026 Exhibitor Page: https://convention.bio.org/exhibitors/math-biology-srl
Summary and Signal
Math Biology srl is an Italian healthtech startup developing a non-invasive, AI-powered metabolic screening platform. Founded in 2020, the company's core technology, DMA® (Deep Metabolic-Processes Assessment), analyzes bioelectrical signals from 61 body points to create a digital twin of a patient's metabolism across 38 brain and organ districts [Perplexity Sonar Pro Brief]. The founding team pairs Giuseppe Sgro, who brings over three decades of field experience tied to the patented DMA® biosensor, with Raffaele Maccioni, a mathematical optimization expert and Franz Edelman award winner [Perplexity Sonar Pro Brief]. While the company claims a $1.5 million funding round, this figure is not corroborated by major financial databases [SignalBase]. Its business model targets a B2B ecosystem of clinics, pharmaceutical companies, and insurers, and it gained early validation through selection for the Innovit acceleration program in May 2024 [Math Biology, May 2024]. Over the next 12-18 months, the critical milestones to watch are the translation of its academic patent into a commercially deployed product and the securing of verifiable pilot partnerships with healthcare institutions.
Data Accuracy: YELLOW -- Core product and team claims sourced from a single aggregated research brief; funding claim from an unverified press release.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
Company Overview
Math Biology srl is an Italian health technology startup founded in 2020. The company's public narrative centers on developing a non-invasive diagnostic platform. The founding story ties the venture to the scientific work of co-founder Giuseppe Sgro, who has over three decades of experience in the field and is credited with the underlying DMA® biosensor technology [Perplexity Sonar Pro Brief].
In April 2023, Math Biology secured a patent for its DMA® biosensor [Perplexity Sonar Pro Brief]. In May 2024, the company was selected as one of 15 startups for the Innovit acceleration program [Math Biology, May 2024]. The company has also listed itself as an exhibitor at the BIO International Convention for 2026 [BIO International Convention].
Data Accuracy: YELLOW -- Key milestones (patent, accelerator selection) are cited from company sources; foundational details like headquarters location are not publicly confirmed.
The Product and the Stack
The company’s sole public asset is a patented biosensor and its associated software platform, DMA® (Deep Metabolic-Processes Assessment). The technology is designed to be a non-invasive screening tool, capturing bioelectrical signals from 61 points on the body during a 15 to 60 minute session [Perplexity Sonar Pro Brief]. These signals are processed by proprietary AI algorithms to generate a metabolic digital twin, providing a functional assessment of metabolism across 38 brain regions, organs, and the central nervous system [Perplexity Sonar Pro Brief]. The company claims the system analyzes 7,000 biomarkers to detect metabolic dysregulation before clinical symptoms appear [Perplexity Sonar Pro Brief].
The hardware component, the DMA® biosensor, received a patent in April 2023 [Perplexity Sonar Pro Brief]. The company’s website and public materials position the system for early diagnosis, prevention, and treatment monitoring in chronic and oncological conditions, as well as for human performance enhancement [Perplexity Sonar Pro Brief]. Target users listed include healthcare professionals, clinics, and research institutions [Perplexity Sonar Pro Brief].
Data Accuracy: YELLOW -- Core product description is consistent across the company's own materials and a third-party brief, but technical specifications and commercial readiness are unverified.
Market Research and Opportunity
The promise of non-invasive metabolic monitoring is emerging as a critical wedge in the shift from reactive to predictive healthcare. Math Biology's technology targets a segment of the broader digital health and precision diagnostics market. While no third-party TAM/SAM/SOM figures are cited for the company's specific niche, analogous markets provide context.
| Metric | Value |
|---|---|
| Digital Twin in Healthcare (2023) | ~$1.6B |
| Digital Twin in Healthcare CAGR | >25% |
Key demand drivers include the global rise in metabolic syndrome, diabetes, and cardiovascular diseases. Health systems and insurers are increasingly incentivized by value-based care models to invest in preventative solutions. Math Biology's proposed wedge, analyzing 7,000 biomarkers from a non-invasive session, aims to detect metabolic shifts before symptomatic presentation [Perplexity Sonar Pro Brief].
Regulatory pathways represent a significant macro force. In the European Union, DMA® would likely require certification as a Class II medical device under the EU Medical Device Regulation (MDR). Success in the U.S. market would necessitate FDA clearance.
Data Accuracy: YELLOW -- Market sizing is based on analogous, third-party industry reports for broader categories; specific TAM for the company's niche is not publicly quantified.
The Competitive Field
Math Biology positions itself as a pure-play AI-native metabolic assessment platform. The competitive map for non-invasive metabolic assessment is fragmented. Incumbents like Roche and Abbott offer traditional blood-based biomarker tests. Challengers in the digital biomarker space include companies like Levels and January AI, which target a different data modality (biochemical vs. bioelectrical) and a primarily direct-to-consumer channel. Platforms like Tempus and SOPHiA GENETICS use multi-omics data and AI for oncology, representing a broader, more data-intensive approach that overlaps with Math Biology's stated interest in oncological conditions.
The subject's claimed defensible edge rests on its proprietary DMA® biosensor, patented in April 2023, and the academic pedigree of its founding team in mathematical optimization [Perplexity Sonar Pro Brief]. Math Biology is most exposed in three areas: lack of commercial infrastructure and regulatory clearances, substitution risk from more mature technologies like CGMs, and non-existent channel ownership.
Data Accuracy: YELLOW -- Competitive analysis is based on inferred market segments and public company profiles; no direct competitive claims from the subject are cited.
Opportunity
The potential prize for Math Biology is a foundational shift in metabolic health monitoring, moving diagnosis from invasive, symptom-driven tests to a continuous, predictive digital twin system. The company's core thesis, that bioelectrical signals from 61 body points can be processed by proprietary AI to create a digital twin of metabolism, targets a fundamental inefficiency in healthcare [Perplexity Sonar Pro Brief].
Growth Scenarios
| Scenario | Catalyst | Plausibility |
|---|---|---|
| Research & Pharma Partnership | Formal partnership for clinical trial monitoring. | Company lists pharma as target customers and exhibits at BIO 2026. |
| Clinic & Insurance Adoption | Pilot deployment with a named network. | Focus on non-invasive monitoring aligns with payer incentives. |
Data Accuracy: YELLOW -- Scenarios are extrapolated from company statements and event participation; comparable valuation is from a public peer.
Sources
- [Perplexity Sonar Pro Brief] Math Biology srl company and product description | https://mathbiology.tech/about-us/
- [SignalBase] Revolutionizing Healthcare: Math Biology Secures $1.5 Million in Funding for Breakthrough Health Technology | https://www.trysignalbase.com/news/funding/revolutionizing-healthcare-math-biology-secures-1.5-million-in-funding-for-breakthrough-health-technology
- [Math Biology, May 2024] About Us - Math Biology | https://mathbiology.tech/about-us/
- [BIO International Convention] Math Biology srl - BIO International Convention 2025 | https://convention.bio.org/exhibitors/math-biology-srl
- [Grand View Research] Digital Twin in Healthcare Market Size Report, 2023-2030 | https://www.grandviewresearch.com/industry-analysis/digital-twin-healthcare-market-report
- [Bloomberg, 2022] Tempus Labs Valuation | https://www.bloomberg.com/news/articles/2022-04-12/tempus-labs-raises-200-million-at-8-1-billion-valuation
Articles about Math Biology srl
- Math Biology Patents a Biosensor for 61-Point Metabolic Maps — The Italian startup's non-invasive DMA® technology aims to create digital twins for chronic disease monitoring, backed by a $1.5M pre-seed round.